J
Jill Corre
Researcher at French Institute of Health and Medical Research
Publications - 107
Citations - 4972
Jill Corre is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 28, co-authored 80 publications receiving 3806 citations. Previous affiliations of Jill Corre include Centre Hospitalier Universitaire de Toulouse & Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells.
Bénédicte Puissant,Corinne Barreau,Philippe Bourin,Cyril Clavel,Jill Corre,Christine Bousquet,Christine Taureau,Béatrice Cousin,Michel Abbal,Patrick Laharrague,Luc Pénicaud,Louis Casteilla,Antoine Blancher +12 more
TL;DR: It is supported that ADAS cells share immunosuppressive properties with BM‐MSCs, and therefore, ADAS cell‐based reconstructive therapy could employ allogenic cells and because of their immunosppressive properties,ADAS cells could be an alternative source to BM‐ MSCs to treat allogenic conflicts.
Journal ArticleDOI
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau,Michel Attal,Cyrille Hulin,Bertrand Arnulf,Karim Belhadj,Lotfi Benboubker,Marie C. Béné,Annemiek Broijl,Hélène Caillon,Denis Caillot,Jill Corre,Michel Delforge,Thomas Dejoie,Chantal Doyen,Thierry Facon,Cécile Sonntag,Jean Fontan,Laurent Garderet,Kon-Siong Jie,Lionel Karlin,Frédérique Kuhnowski,Jérôme J. Lambert,Xavier Leleu,Pascal Lenain,Margaret Macro,Claire Mathiot,Frédérique Orsini-Piocelle,Aurore Perrot,Anne-Marie Stoppa,Niels W.C.J. van de Donk,Soraya Wuilleme,Sonja Zweegman,Brigitte Kolb,Cyrille Touzeau,Murielle Roussel,Mourad Tiab,Jean-Pierre Marolleau,Nathalie Meuleman,Marie-Christiane Vekemans,Matthijs Westerman,Saskia K. Klein,Mark-David Levin,Jean Paul Fermand,Martine Escoffre-Barbe,Jean-Richard Eveillard,Reda Garidi,Tahamtan Ahmadi,Sen Zhuang,Christopher Chiu,Lixia Pei,Carla de Boer,Elena Smith,William Deraedt,Tobias Kampfenkel,Jordan M. Schecter,Jessica Vermeulen,Hervé Avet-Loiseau,Pieter Sonneveld +57 more
TL;DR: D-VTd before and after autologous stem-cell transplantation improved depth of response and progression-free survival with acceptable safety and CASSIOPEIA is the first study showing the clinical benefit of daratumumab plus standard of care in transplant-eligible patients with newly diagnosed multiple myeloma.
Journal ArticleDOI
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
Jill Corre,Karène Mahtouk,Michel Attal,Mélanie Gadelorge,Anne Huynh,Sandrine Fleury-Cappellesso,Clotaire Danho,Patrick Laharrague,Bernard Klein,Thierry Rème,Philippe Bourin +10 more
TL;DR: Bone marrow mesenchymal stem cells, the only long-lived cells of the bone marrow microenvironment, are abnormal and could create a very efficient niche to support the survival and proliferation of the myeloma cells.
Journal ArticleDOI
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot,Valérie Lauwers-Cances,Jill Corre,Jill Corre,Nelly Robillard,Cyrille Hulin,Marie-Lorraine Chretien,Thomas Dejoie,Sabrina Maheo,Sabrina Maheo,Anne-Marie Stoppa,Brigitte Pegourie,Lionel Karlin,Laurent Garderet,Bertrand Arnulf,Chantal Doyen,Nathalie Meuleman,Bruno Royer,Jean-Richard Eveillard,Lotfi Benboubker,Mamoun Dib,Olivier Decaux,Arnaud Jaccard,Karim Belhadj,Sabine Brechignac,Brigitte Kolb,Cecile Fohrer,Mohamad Mohty,Margaret Macro,Paul G. Richardson,Victoria Carlton,Martin Moorhead,Thomas D. Willis,Malek Faham,Kenneth C. Anderson,Jean-Luc Harousseau,Xavier Leleu,Thierry Facon,Philippe Moreau,Michel Attal,Hervé Avet-Loiseau,Hervé Avet-Loiseau,Nikhil C. Munshi +42 more
TL;DR: The findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.
Journal ArticleDOI
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome
Murielle Roussel,Valérie Lauwers-Cances,Nelly Robillard,Cyrille Hulin,Xavier Leleu,Lotfi Benboubker,Gerald Marit,Philippe Moreau,Brigitte Pegourie,Denis Caillot,Christophe Fruchart,Anne-Marie Stoppa,Catherine Gentil,Soraya Wuilleme,Anne Huynh,Benjamin Hebraud,Jill Corre,Marie-Lorraine Chretien,Thierry Facon,Hervé Avet-Loiseau,Michel Attal +20 more
TL;DR: The transplantation program with RVD induction and consolidation followed by lenalidomide maintenance produced high-quality responses and showed favorable tolerability in patients with newly diagnosed MM.